The Hevolution Foundation in Riyadh, Saudi Arabia, has announced a $20 million (SAR 75 million) investment in San Fransisco-based Aeovian Pharmaceuticals to advance promising therapies that target the mTORC1 biological pathway.

The gift will support a $50 million (SAR 188 million) Series A financing extension in the biopharmaceutical company to advance its platform of selective mTORC1 inhibitors, which could lead to several promising therapies to address unmet needs associated with neurological diseases and other challenges of aging.

“Hevolution stands out as a global nonprofit, having allocated over $250 million toward healthspan research grants and partnerships since 2021,” said Hevolution CEO Mehmood Khan. “Our inaugural impact investment in Aeovian is another landmark moment for us, furthering our mission by laying the groundwork to encourage more companies and investors to engage with the healthspan field through promising early-stage biotech companies like Aeovian. We remain unwavering in our commitment to drive growth, innovation, and cooperation in this scientific field, with the ultimate goal of enhancing healthy human healthspan.”

(Photo credit: Getty Images/Gorodenkoff)